Marizyme, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRZM research report →
Companymarizyme.com
Marizyme, Inc. , a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties.
- CEO
- David L. Barthel
- IPO
- 2010
- Employees
- 13
- HQ
- Jupiter, FL, US
Price Chart
Valuation
- Market Cap
- $39.54K
- P/E
- -0.00
- P/S
- 0.06
- P/B
- -0.00
- EV/EBITDA
- -0.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 36.99%
- Op Margin
- -5278.10%
- Net Margin
- -10767.77%
- ROE
- -1089.84%
- ROIC
- -175.14%
Growth & Income
- Revenue
- $645.81K · 176.60%
- Net Income
- $-69,539,336 · -82.20%
- EPS
- $-1.53 · -62.77%
- Op Income
- $-34,086,516
- FCF YoY
- 56.83%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.98
- Avg Volume
- 1.57K
Get TickerSpark's AI analysis on MRZM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 21, 23 | Braeden Lichti | other | 3,815,294 |
| Dec 21, 23 | Braeden Lichti | other | 2 |
| Jun 29, 23 | Lichti Braeden | sell | 106,327 |
| Jul 7, 23 | Lichti Braeden | sell | 97,000 |
| Aug 29, 23 | Lichti Braeden | sell | 105,000 |
| Jun 29, 23 | Lichti Braeden | buy | 106,327 |
| Jul 7, 23 | Lichti Braeden | buy | 97,000 |
| Aug 29, 23 | Lichti Braeden | buy | 105,000 |
| Apr 14, 23 | Dhaduk Vithalbhai D | other | 1,063,938 |
| Apr 14, 23 | Dhaduk Vithalbhai D | other | 1,063,938 |
Our MRZM Coverage
We haven't published any research on MRZM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MRZM Report →